AUS
NZ
UK
CA
USA
IND
Healt
ResMed (ASX:RMD) Leads Healthcare Stocks as EOFY Flows Shift Focus
June 22, 2026 09:17 PM AEST| By SamHealthcare stocks are regaining attention as EOFY flows, valuation discipline and device diagnostics momentum reshape market focus, with ResMed, Cochlear and Pro Medicus highlighting the importance of visibility, execution and cash-flow strength.
Is Cochlear (ASX:COH) Facing a Healthcare Stock in ASX 200?
June 22, 2026 03:47 PM AEST| By SamCochlear (ASX:COH) remains under pressure after a major earnings downgrade, with surgery delays and healthcare system constraints weighing on short-term performance within the ASX 200 healthcare sector.
Are (ASX:RMD) and Healthcare Shares Near a Turning Point?
June 22, 2026 03:47 PM AEST| By SamASX healthcare stocks remain under pressure, with ResMed (ASX:RMD) at the centre of valuation discussions as investors reassess sector positioning and long-term growth outlook.
Is CSL (ASX:CSL) Becoming a Value Play After Its Sharp 2026 Drop?
June 22, 2026 03:45 PM AEST| By SamCSL faces renewed valuation debate after a sharp 2026 decline, with investors reassessing its plasma business, earnings outlook, and long-term role in Australia’s healthcare sector.
DroneShield (ASX:DRO): Are These Financially Strong Stocks Flying Under the Radar?
June 22, 2026 11:29 AM AEST| By SamDroneShield, IperionX and Sigma Healthcare are drawing attention through strong financial positions, sector-specific growth opportunities and exposure to major long-term economic trends.
Pro Medicus (ASX:PME): Why This Global Healthcare Leader Is Drawing Fresh Attention
June 22, 2026 10:20 AM AEST| By SamHealthcare technology companies remain in focus as recurring revenue models, digital healthcare adoption and artificial intelligence continue reshaping the sector.
What’s Driving CSL (ASX:CSL) ASX 20 After Its Latest Strategic Reset?
June 22, 2026 09:54 AM AEST| By SamCSL remains a leading biotechnology company with global operations. Market attention is centred on restructuring efforts, operational efficiency and its long-term role in advanced healthcare innovation.
ImpediMed (ASX:IPD): Why Has This Healthcare Stock Suddenly Grabbed Attention?
June 21, 2026 02:42 PM AEST| By SamImpediMed is drawing renewed attention following major insider buying activity, healthcare technology innovation and expanding opportunities in patient monitoring solutions.
CSL (ASX:CSL): Why Are These Market Giants Facing Fresh Questions?
June 21, 2026 02:28 PM AEST| By SamCSL, Steadfast and Wesfarmers continue attracting attention through healthcare innovation, insurance distribution developments and retail transformation initiatives across the Australian market.
Mesoblast (ASX:MSB) ASX 300 Faces a Bigger Commercial Test
June 21, 2026 02:25 PM AEST| By SamMesoblast is entering a new phase where commercial delivery, therapy adoption, pipeline progress, and financial discipline are becoming more important than development milestones alone.
Why 4DX (ASX:4DX) Is Drawing Fresh Healthcare Attention
June 21, 2026 02:18 PM AEST| By Team Kalkine Media4DMedical is gaining attention as investors assess respiratory imaging innovation, healthcare adoption, commercial execution and the growing importance of evidence-based growth across healthcare technology.
CSL (ASX:CSL) and ASX 200 Healthcare Shift: What’s Fueling Fresh Market Attention?
June 21, 2026 01:56 PM AEST| By SamHealthcare stocks have returned to the spotlight on the Australian market, with leading companies helping improve sector sentiment and reigniting discussion around the industry’s broader recovery prospects.
Why DroneShield (ASX:DRO) Is Leading the Defence Conversation Alongside IPX and SIG
June 20, 2026 09:50 AM AEST| By SamDroneShield, IperionX and Sigma Healthcare continue attracting attention through exposure to defence technology, critical minerals and healthcare infrastructure themes.
CSL (ASX:CSL) Leads Healthcare Comeback, But Is the Rally Real?
June 19, 2026 04:57 PM AEST| By SamAustralia's healthcare sector rebounded sharply as capital shifted from resources into growth stocks, lifting CSL, Cochlear, ResMed, Pro Medicus and Telix and renewing attention on the sector's longer-term outlook.
Cochlear (ASX:COH): The Shock That Sent a Healthcare Giant Tumbling
June 19, 2026 04:55 PM AEST| By SamCochlear’s earnings downgrade triggered a sharp market reassessment as weaker referrals, hospital constraints and cost-of-living pressures disrupted growth expectations for the hearing-implant leader.
Could Lumos Diagnostics Be Approaching a Turning Point?
June 19, 2026 11:47 AM AEST| By SamLumos Diagnostics is gaining attention as analysts assess its path towards profitability, supported by healthcare sector demand and a debt-free balance sheet.
Cynata’s Double Setback: What Happens to the Cymerus Platform Now?
June 19, 2026 11:37 AM AEST| By SamCynata’s latest clinical setback has intensified focus on the future of the Cymerus platform, with management now reviewing strategic options following recent trial disappointments.
After a Brutal Slide, Could CSL Be Preparing a Comeback?
June 19, 2026 09:56 AM AEST| By SamCSL remains a major focus within Australia's healthcare sector as analysts evaluate valuation, innovation capabilities, and the company's position as a global biotechnology leader.
Telix Expands Global Cancer Strategy Through Landmark Partnerships
June 18, 2026 09:30 PM AEST| By SamTelix is accelerating its global radiopharmaceutical ambitions through major healthcare collaborations, theranostics research initiatives and expanded funding, reinforcing its growing presence in advanced cancer imaging and targeted treatment develop...
Healthcare's Surprise Comeback: Is This the Turn Investors Missed?
June 18, 2026 09:21 PM AEST| By SamAustralia's healthcare sector has staged a notable recovery, led by CSL and supported by Cochlear, ResMed, Pro Medicus and Telix Pharmaceuticals as the market reassesses valuations and long-term sector strengths.
Advertise your brand on Kalkine Media